CPX-351 for the Treatment of Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (TAML) or AML with Myelodysplasia-Related Changes (AML-MRC)- An Analysis of Clinical Benefit
May 1, 2018, 00:00
10.1016/j.jval.2018.04.087
https://www.valueinhealthjournal.com/article/S1098-3015(18)30387-5/fulltext
Title :
CPX-351 for the Treatment of Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (TAML) or AML with Myelodysplasia-Related Changes (AML-MRC)- An Analysis of Clinical Benefit
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30387-5&doi=10.1016/j.jval.2018.04.087
First page :
Section Title :
Open access? :
No
Section Order :
309